Mesoblast LTD (MEOBF) — SEC Filings

Overview

Mesoblast LTD (MEOBF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 30, 2025: On December 30, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This report is filed as a Form 6-K with the SEC, indicating it's a report from a foreign private issuer. The company is incorporated in Australia and its CEO is Silviu Itescu.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 49 neutral. The dominant filing sentiment for Mesoblast LTD is neutral.

Filing Type Overview

Mesoblast LTD (MEOBF) has filed 49 6-K, 1 SC 13G/A with the SEC between Dec 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Mesoblast Ltd Files 6-K Report — 6-K · Dec 30, 2025 Risk: low
  On December 30, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This report is filed as a Form 6-K with the SE
• 6-K Filing — 6-K · Dec 29, 2025
• Mesoblast Ltd Files 6-K on Unquoted Equity Securities — 6-K · Dec 18, 2025 Risk: low
  On December 17, 2025, Mesoblast Limited filed a Form 6-K with the SEC, reporting a new issue announcement to the Australian Securities Exchange. This announceme
• Mesoblast Ltd Files 6-K with SEC — 6-K · Dec 12, 2025 Risk: low
  On December 12, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The fili
• 6-K Filing — 6-K · Dec 4, 2025
• 6-K Filing — 6-K · Nov 26, 2025
• 6-K Filing — 6-K · Nov 25, 2025
• 6-K Filing — 6-K · Nov 24, 2025
• Mesoblast Ltd Files 6-K Report — 6-K · Nov 17, 2025 Risk: low
  On November 17, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This filing is a Form 6-K report for the month
• 6-K Filing — 6-K · Nov 5, 2025
• Mesoblast Files Director Interest & New Issue Notices — 6-K · Oct 29, 2025 Risk: medium
  On October 28, 2025, Mesoblast Limited filed a new issue announcement and a change of director's interest notice (Appendix 3Y) with the Australian Securities Ex
• Mesoblast Ltd Files Annual Report — 6-K · Oct 28, 2025 Risk: low
  On October 28, 2025, Mesoblast Limited filed its Annual Report to Shareholders with the Australian Securities Exchange. The report is incorporated into this For
• Mesoblast Ltd Files Quarterly Report — 6-K · Oct 22, 2025 Risk: medium
  Mesoblast Limited filed a quarterly report (Appendix 4C) with the Australian Securities Exchange on October 20, 2025, for the quarter ended September 30, 2025.
• Mesoblast Ltd. Files 6-K for Unquoted Equity Securities — 6-K · Oct 15, 2025 Risk: medium
  On October 15, 2025, Mesoblast Limited filed a Form 6-K with the SEC, reporting a new issue of unquoted equity securities as announced to the Australian Securit
• Mesoblast Ltd Files 6-K Report — 6-K · Oct 7, 2025 Risk: low
  On October 7, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This filing is a Form 6-K report for the month o
• Mesoblast Ltd Files 6-K with SEC — 6-K · Oct 3, 2025 Risk: low
  On October 3, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a press release previously announced on the Australian Securities Exchange. This
• Mesoblast Ltd Files 6-K with ASX Announcement — 6-K · Sep 29, 2025 Risk: medium
  Mesoblast Limited filed a Form 6-K on September 29, 2025, reporting a new release announcement made on September 26, 2025, to the Australian Securities Exchange
• Mesoblast Files New Issue and Director Interest Notices — 6-K · Sep 15, 2025 Risk: low
  On September 12, 2025, Mesoblast Limited filed a new issue announcement and a change of director's interest notice (Appendix 3Y) with the Australian Securities
• Mesoblast Ltd Files 6-K Report — 6-K · Sep 4, 2025 Risk: low
  On September 4, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a press release announced on the Australian Securities Exchange. The filing is
• Mesoblast Ltd Files 6-K with ASX Announcements — 6-K · Aug 29, 2025 Risk: low
  On August 29, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement and investor presentation. The company, incorporated i
• Mesoblast Ltd Files August 2025 6-K Report — 6-K · Aug 27, 2025 Risk: low
  On August 27, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. This filin
• Mesoblast Ltd Files Quarterly Report — 6-K · Jul 18, 2025 Risk: low
  On July 18, 2025, Mesoblast Limited filed its Appendix 4C quarterly report for the period ending June 30, 2025. The filing details the company's cash flow activ
• Mesoblast Ltd. Files Appendix 3H with ASX — 6-K · Jul 15, 2025 Risk: low
  On July 14, 2025, Mesoblast Limited filed an Appendix 3H with the Australian Securities Exchange, announcing the cessation of securities. This filing is part of
• Mesoblast Ltd Files 6-K with SEC — 6-K · Jul 1, 2025 Risk: low
  On July 1, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. This filing i
• Mesoblast Ltd Files 6-K with SEC — 6-K · Jun 12, 2025 Risk: low
  On June 12, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The filing d
• Mesoblast Ltd Files 6-K Report — 6-K · May 15, 2025 Risk: low
  On May 15, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This filing is a Form 6-K report for the month of M
• Mesoblast Ltd Files Quarterly Report — 6-K · Apr 30, 2025 Risk: medium
  On April 30, 2025, Mesoblast Limited filed a quarterly report (Appendix 4C) with the Australian Securities Exchange for the quarter ended March 31, 2025. The co
• Mesoblast Ltd Appoints Dr. Fred Hassan to Board — 6-K · Apr 29, 2025 Risk: low
  On April 29, 2025, Mesoblast Limited announced the appointment of a new director, Dr. Fred Hassan, to its Board of Directors. Dr. Hassan brings extensive experi
• Mesoblast Ltd Files 6-K with Director Interest Notice — 6-K · Apr 24, 2025 Risk: low
  On April 24, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new issue announcement and a change of director's interest notice (Appendix 3Y)
• Mesoblast Ltd Files 6-K with SEC, Incorporates ASX Announcement — 6-K · Apr 17, 2025 Risk: low
  On April 17, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. This filing
• Mesoblast Ltd Files Securities Cessation Notice — 6-K · Apr 15, 2025 Risk: low
  On April 14, 2025, Mesoblast Limited filed a notification of cessation of securities (Appendix 3H) with the Australian Securities Exchange. This filing indicate
• Mesoblast Files Director Interest Change & New Issue Announcement — 6-K · Apr 9, 2025 Risk: low
  On April 8, 2025, Mesoblast Limited filed a new issue announcement and a change of director's interest notice (Appendix 3Y) with the Australian Securities Excha
• Mesoblast Ltd Files 6-K with ASX Announcement — 6-K · Apr 4, 2025 Risk: low
  On April 4, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. This filing
• Mesoblast Ltd Files 6-K with SEC — 6-K · Apr 3, 2025 Risk: low
  On April 3, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. This filing
• Mesoblast Ltd Files 6-K with SEC — 6-K · Mar 31, 2025 Risk: low
  On March 31, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The filing
• Mesoblast Ltd Files 6-K Update — 6-K · Mar 27, 2025 Risk: low
  On March 27, 2025, Mesoblast Limited filed a Form 6-K with the SEC, incorporating by reference a new release announcement made to the Australian Securities Exch
• Mesoblast Ltd Files 6-K with SEC — 6-K · Mar 14, 2025 Risk: low
  On March 14, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a press release announcement made to the Australian Securities Exchange. The filin
• Mesoblast Ltd Files 6-K with SEC — 6-K · Mar 13, 2025 Risk: low
  On March 13, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The filing
• Mesoblast Ltd Files 6-K with SEC — 6-K · Mar 12, 2025 Risk: low
  On March 12, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The filing
• Mesoblast Ltd Files March 2025 6-K Report — 6-K · Mar 7, 2025 Risk: low
  On March 6, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This filing is a Form 6-K report for the month of
• Mesoblast Ltd Files 6-K with ASX Updates — 6-K · Feb 28, 2025 Risk: low
  On February 27, 2025, Mesoblast Limited filed a new release announcement and an investor presentation with the Australian Securities Exchange. This filing is a
• Mesoblast Ltd. Files 6-K with Financial Updates — 6-K · Feb 27, 2025 Risk: low
  Mesoblast Ltd. filed a 6-K report for the period ending December 31, 2024. The filing includes financial data for the six months ended December 31, 2024, and co
• Mesoblast Ltd. Files 6-K with ASX Announcement — 6-K · Feb 25, 2025 Risk: low
  On February 24, 2025, Mesoblast Limited announced a new release filed with the Australian Securities Exchange. The company is incorporated in Australia and its
• Mesoblast Ltd Files 6-K with SEC — 6-K · Feb 14, 2025 Risk: low
  On February 14, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The fili
• Mesoblast Ltd Files Quarterly Report — 6-K · Jan 31, 2025 Risk: low
  On January 31, 2025, Mesoblast Limited filed a quarterly Appendix 4C report with the Australian Securities Exchange. This report covers the period ending Januar
• Mesoblast Ltd Announces New Securities Issue — 6-K · Jan 24, 2025 Risk: medium
  On January 17, 2025, Mesoblast Limited announced a new securities issue and applied for quotation of these securities on the Australian Securities Exchange. Thi
• Mesoblast Raises AUD 100M for Remestemcel-L — 6-K · Jan 16, 2025 Risk: medium
  On January 14, 2025, Mesoblast Limited announced the completion of a placement of new ordinary shares, raising approximately AUD 100 million. The placement was
• Mesoblast Ltd Announces New Share Issuance — 6-K · Dec 23, 2024 Risk: medium
  On December 20, 2024, Mesoblast Limited announced a new share issuance and filed change of directors' interest notices (Appendix 3Y) with the Australian Securit
• Mesoblast Ltd Files 6-K Report — 6-K · Dec 20, 2024 Risk: low
  On December 18, 2024, Mesoblast Limited announced a new release filed with the Australian Securities Exchange. This filing is a Form 6-K report for the month of
• SC 13G/A Filing — SC 13G/A · Dec 16, 2024

Risk Profile

Risk Assessment: Of MEOBF's 43 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 35 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Silviu Itescu
• Dr. Fred Hassan

Top Tags

foreign-private-issuer (14) · disclosure (13) · filing (12) · sec-filing (8) · regulatory-filing (7) · regulatory-update (6) · new-issue (5) · quarterly-report (4) · biotech (4) · reporting (3)

Key Numbers

• SEC File Number: 001-37626 — Identifies Mesoblast Limited's filings with the SEC.
• Period End Date: 2024-12-31 — Latest financial reporting period
• Comparative Period End Date: 2023-12-31 — Previous financial reporting period for comparison
• Capital Raised: AUD 100M — Funds secured through a placement to advance remestemcel-L and for working capital.

Related Companies

MESO

Frequently Asked Questions